Home > Insider Trading > Filing (0000921895-23-002167)

Filing Details

Accession Number:: 0000921895-23-002167
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-09-14 16:25:27
Reporting Period:: 2023-09-12

Accepted Time:: 2023-09-14 16:25:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1750284	Olema Pharmaceuticals Inc.	OLMA	Investment Advice (6282)	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
918923	P L Fund Value Biotechnology	44 Montgomery St. 40Th Floor San Francisco CA 94104	Yes	No	No	Yes
1055947	P/Il L Partners Bvf	44 Montgomery St. 40Th Floor San Francisco CA 94104	Yes	No	Yes	No
1056807	Bvf Inc/Il	44 Montgomery St. 40Th Floor San Francisco CA 94104	Yes	No	Yes	No
1102444	Biotechnology Value Fund Ii Lp	44 Montgomery St. 40Th Floor San Francisco CA 94104	Yes	No	No	Yes
1233840	N Mark Lampert	44 Montgomery St. 40Th Floor San Francisco CA 94104	Yes	No	Yes	No
1660683	Biotechnology Value Trading Fund Os Lp	P.o. Box 309 Ugland House Grand Cayman E9 KY1-1104	Yes	No	No	Yes
1660684	Ltd. Os Partners Bvf	P.o. Box 309 Ugland House Grand Cayman E9 KY1-1104	Yes	No	No	Yes
1803805	Bvf I Gp Llc	44 Montgomery St. 40Th Floor San Francisco CA 94104	Yes	No	No	Yes
1803806	Bvf Ii Gp Llc	44 Montgomery St. 40Th Floor San Francisco CA 94104	Yes	No	No	Yes
1803809	Bvf Gp Holdings Llc	44 Montgomery St. 40Th Floor San Francisco CA 94104	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2023-09-12	775,278	$9.84	4,688,954	No	4	P	Direct
Common Stock, $0.0001 Par Value	Acquisiton	2023-09-12	677,853	$9.84	3,584,512	No	4	P	Direct
Common Stock, $0.0001 Par Value	Acquisiton	2023-09-12	52,801	$9.84	524,151	No	4	P	Direct
Common Stock, $0.0001 Par Value	Acquisiton	2023-09-14	99,556	$0.00	99,556	No	4	J	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	J	Indirect	See footnote

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock, $0.0001 Par Value	Stock Option (Right to buy)	$7.84	2033-06-15	21,520	21,520	Indirect
Common Stock, $0.0001 Par Value	Stock Option (Right to buy)	$19.00	2030-11-17	21,520	21,520	Indirect
Common Stock, $0.0001 Par Value	Stock Option (Right to buy)	$19.00	2030-11-17	21,520	21,520	Indirect
Common Stock, $0.0001 Par Value	Stock Option (Right to buy)	$19.00	2030-11-17	21,520	21,520	Indirect
Common Stock, $0.0001 Par Value	Stock Option (Right to buy)	$27.66	2031-06-08	21,520	21,520	Indirect
Common Stock, $0.0001 Par Value	Stock Option (Right to buy)	$3.61	2032-06-16	21,520	21,520	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2033-06-15	21,520	21,520	Indirect
2030-11-17	21,520	21,520	Indirect
2030-11-17	21,520	21,520	Indirect
2030-11-17	21,520	21,520	Indirect
2031-06-08	21,520	21,520	Indirect
2032-06-16	21,520	21,520	Indirect

Footnotes

This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
The Issuer entered into a securities purchase agreement with certain purchasers, including certain of the Reporting Persons (the "Purchasers"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the "Private Placement") shares of the Issuer's Common Stock at a per share purchase price equal to $9.84.
Shares of the Issuer's Common Stock purchased in the Private Placement.
Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account.
Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date.
The shares subject to the option have fully vested.
The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to Mr. Hrustanovic's continuous service on the Issuer's board of directors through each applicable vesting date.
The shares subject to the option have fully vested.
The shares subject to the option have fully vested.